Table 3.

Odds of patient with a molecular signature of non-response having an inadequate response to TNFi therapy

	AUC	Odds ratio (95% CI; p value)
Prospective observational, naïve
ACR50, 3 months	0.67	3.7 (1.7–8.0; 0.0007)
ACR50, 6 months	0.64	4.1 (2.0–8.3; 0.0001)
ACR70, 3 months	0.66	2.5 (1.0–6.2; 0.05)
ACR70, 6 months	0.70	6.7 (2.7–16.7; < 0.0001)
CDAI LDA, 3 months	0.65	3.4 (1.6–7.0; 0.0009)
CDAI LDA, 6 months	0.68	3.6 (1.8–7.2; 0.0002)
CDAI remission, 3 months	0.70	2.6 (1.1–6.1; 0.03)
CDAI remission, 6 months	0.74	8.8 (2.9–27.3; < 0.0001)
DAS28-CRP LDA, 3 months	0.69	4.1 (1.9–9.1; 0.0005)
DAS28-CRP LDA, 6 months	0.67	3.6 (1.8–7.3; 0.0003)
DAS28-CRP remission, 3 months	0.60	1.4 (0.6–3.1; 0.43)
DAS28-CRP remission, 6 months	0.73	5.8 (2.6–13.0; < 0.0001)
Prospective observational, TNFi-exposed
ACR50, 6 months	0.66	3.3 (1.5–7.4; 0.0038)
ACR70, 6 months	0.73	6.0 (2.0–17.7; 0.0007)
CDAI LDA, 6 months	0.72	5.5 (2.4–12.4; < 0.0001)
CDAI remission, 6 months	0.83	26.6 (3.4–209.8; < 0.0001)
DAS28-CRP LDA, 6 months	0.69	6.7 (2.8–16.1; < 0.0001)
DAS28-CRP remission, 6 months	0.62	2.1 (0.9–5.0; 0.0878)

AUC area under the curve, CI confidence interval, ACR American College of Rheumatology, CDAI clinical disease activity index, LDA low disease activity, DAS28-CRP disease activity score 28-joint count with C-reactive protein, TNFi tumor necrosis factor-α inhibitor